|
|
Vaccine Detail
|
IMM-101 |
| Vaccine Information |
- Vaccine Name: IMM-101
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007622
- Type: Inactivated or "killed" vaccine
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
- Description: IMM-101, a suspension of heat-killed whole cell Mycobacterium obuense. IMM-101 is safe and well tolerated and there is a rationale for studying IMM-101 at a nominal 1.0-mg dose to complement conventional cytotoxic therapy for patients with advanced cancer (Stebbing et al., 2012).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Induced specific maturation of monocyte-derived dendritic cells (DCs), which when placed in culture with naive CD4+ T cells is associated with inhibition of IL-4 and induction of CD25+FoxP3+ cells (Stebbing et al., 2012).
|
| References |
Stebbing et al., 2012: Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, Brunet LR, Grange J, Mudan S. An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012; 23(5); 1314-1319. [PubMed: 21930686].
|
|
